Mid-stage data reveal safety and efficacy signals supporting potential shift in frontline treatment for higher-risk MDS patients.
Mid-stage data reveal safety and efficacy signals supporting potential shift in frontline treatment for higher-risk MDS patients.
Once-monthly subcutaneous treatment offers new option for preventing hereditary angioedema attacks across all patient types from therapy initiation.
Clinical trial results underscore safety and diagnostic accuracy for radiopharmaceutical imaging; Clarity pursues regulatory filings and wider manufacturing …
Combination of ZYNLONTA® and glofitamab (COLUMVI®) shows durable complete responses and manageable safety profile in Phase 1b study.
Early Access Program data supports robust efficacy and safety, reinforcing results from the pivotal ARES trial and strengthening …
This approval adds a key anti-inflammatory eye drop to Amneal’s Affordable Medicines portfolio, with a commercial launch planned …
June 11 reveals critical progress across cell and gene therapies, metabolic disease drug research, and strategic industry partnerships …
June 10 sees robust momentum in biotechnology with novel therapeutic developments, advanced clinical trials, key industry events, and …
The FDA’s June 9 drug approvals bring new preventive options for infants at risk of RSV, innovative combination …
Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
